Avam is a pioneering startup in the fields of molecular biology and microbiology. Focusing on bridging the gap "From Lab to Life," the company aims to empower scientists and healthcare professionals in advancing research and improving patient care. Their portfolio includes PCR systems, sequencing technologies, extraction platforms, and the specialized InMicro™ microbiology product line, catering to research institutions, clinical laboratories, biotechnology companies, and healthcare facilities globally. Founded in 2017 and based in Tampa, Florida, Avam distinguishes itself with scientific excellence and agility, offering same-day customization and rapid response to emerging customer needs. The company's offerings span from advanced molecular diagnostic platforms to comprehensive microbiology solutions, impacting clinical diagnostics, life science research, food safety, environmental testing, and forensics. Avam's commitment to continuous innovation and customer-focused solutions aligns with its mission to accelerate the journey from scientific discovery to practical application. By helping laboratories streamline their workflows, enhance productivity, and achieve breakthrough results, Avam contributes to benefiting society at large.
There is no investment information
No recent news or press coverage available for Avam.
We care about your data, and we'd love to use cookies make your experience better.
